Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2018-10-31 Regulatory Filings
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment
Regulatory Filings Classification · 1% confidence The document is a press release dated October 31, 2018, announcing that Verona Pharma has enrolled the last patient in a Phase 2 clinical trial for RPL554 and expects top-line data in January 2019. It details the trial design, endpoints, and provides background information on COPD and the company's drug candidate. This type of announcement, focusing on clinical trial progress and expected results timing, is characteristic of an Earnings Release (ER) or a general press release updating investors on operational milestones. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, the most appropriate classification for a press release announcing key operational/clinical updates and expected data release is Earnings Release (ER), as these often accompany or precede formal earnings reports and focus on key performance indicators (in this case, clinical progress). Alternatively, given the focus on clinical trial progress and data timing, it could be seen as a general Investor Relations update, but ER is often used for such time-sensitive operational news. Since it is not explicitly an 'Earnings Release' header, but rather a clinical update, and it doesn't fit other specific categories, I will check the definitions again. It is not a 'Report Publication Announcement' (RPA) because it is announcing the *completion of enrollment* and *expected data availability*, not the publication of a formal report itself. It is a substantive update. Given the context of clinical trial progress announcements in the biopharma sector, this is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure not covered elsewhere. However, ER is the best fit for a press release detailing operational milestones and future data timelines.
2018-10-31 English
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
Report Publication Announcement Classification · 1% confidence The document is a press release from Verona Pharma announcing the date they will report their audited financial results for the nine months ended September 30, 2018, and that they will host a conference call to discuss these results. This is a classic announcement of an upcoming financial report release and associated call, not the full report itself (which would likely be an IR or 10-K/IR filing). Since the primary purpose is to announce the timing of the release of financial results and the subsequent conference call, it fits best under 'Report Publication Announcement' (RPA), as it is announcing the publication of a report (the nine-month results). It is too specific for the general 'RNS' fallback, and while it mentions a conference call (CT), the main focus is the report release announcement.
2018-10-30 English
Nuvec® research update
Environmental & Social Information Classification · 1% confidence The document begins with an 'RNS Number' and is dated October 29, 2018. It is titled 'Nuvec® research update' and details recent scientific findings regarding the company's delivery system. The text concludes with contact information and a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure strongly indicates a general regulatory announcement disseminated via the RNS system, rather than a comprehensive financial report (like 10-K or IR) or a specific management/board change. Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIV, DIRS, or ER), the appropriate fallback category is Regulatory Filings (RNS). The document length (5028 chars) is substantial enough to be a substantive update, but its primary function here is regulatory dissemination via the RNS service.
2018-10-29 English
Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharma’s RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference
Earnings Release Classification · 1% confidence The document is a press release dated October 26, 2018, announcing the presentation of positive pre-clinical and Phase 2a trial data for the drug RPL554 at a conference. It contains key financial/clinical highlights, quotes from management, and forward-looking statements. This format, which releases key results before a full report (like a 10-K or IR), aligns perfectly with an Earnings Release (ER) or a general announcement of clinical progress. Since it focuses on announcing the results of a trial and key data points rather than being a transcript (CT) or a formal comprehensive report (IR/10-K), 'ER' (Earnings Release) is the most appropriate classification for this type of clinical/business update announcement, even though it's not strictly quarterly earnings. Given the context of biopharma press releases announcing trial data, ER is often used for significant clinical updates that drive investor interest, similar to how earnings drive interest. It is not a formal report (IR/10-K) but an announcement of findings. FY 2018
2018-10-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified by the 'RNS Number' header and contains the standard structure for a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The RNS (Regulatory News Service) branding at the end confirms its nature as a regulatory announcement, but the specific content points to 'MRQ' (Major Shareholding Notification) over the general 'RNS' fallback.
2018-10-23 English
Research collaboration for novel DNA vaccine
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement from the London Stock Exchange's news service (RNS). The content describes a new research collaboration and funding commitment for a project involving the company's technology (Nuvec®) and a university's DNA vaccine. This is a specific operational update concerning partnerships and research, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend announcement (DIV). Since it is a formal announcement released via the RNS system detailing a business development, it fits best under the general 'Regulatory Filings' category, which serves as a fallback for specific operational news releases that aren't covered by other codes like ER or CAP. Given the explicit mention of 'RNS Number' and the nature of the announcement, RNS is the most appropriate classification.
2018-10-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.